New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis

Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab

“…These findings are consistent with previous studies of other autoimmune rheumatoid diseases, which reported that 25-71% and 4-46% patients became positive for ANA and anti-dsDNA antibodies after IFX initiation in case of psoriasis and rheumatoid arthritis [32,37,38]. In these previous studies, a small number of patients had lupus-like symptoms [39][40][41]. Suhler EB et al also reported the results of a prospective study in which 23 patients with non-infectious uveoretinitis including 4 of BD patients were enrolled [42].…”

Infliximab-Induced Lupus-Like Syndrome in a Female Patient With Rheumatoid Arthritis (A Case Report): An Accident or Regularity?

“…В первые го-ды после применения ингибиторов ФНОα большинство случаев ВИИФНОα были связаны с ИНФ, которым лечи-лись больные РА [9][10][11], псориатическим артритом или с болезнью Крона [12,13]. ЭТЦ [14][15][16][17][18][19][20] и АДА [21,22], по-явившиеся позже ИНФ, также индуцируют ВИИФНОα. Обследование всех французских центров, применяющих ингибиторы ФНОα для лечения ревматических заболева-ний, выявило 22 больных с ВИИФНОα [23].…”

Infliximab‐related lupus and associated valvulitis: A case report and review of the literature

“…The counter argument that anti-TNF␣ drugs do indeed induce SLE in patients with rheumatoid arthritis is that some of the case reports in the literature have documented negative ANAs and negative anti-dsDNA antibodies prior to the patient being started on the biologic agent in question (3,5,6). In many of these reported cases, in addition to clinical improvement, other serologic abnormalities such as hypocomplementemia, high-titer anti-dsDNA antibodies, and high ESR reversed with cessation of the biologic agent.…”